Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of pegzilarginase in arginase 1 deficiency
2018-003163-67Phase 2Unknown
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Oct 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegzilarginase in arginase 1 deficiency (ARG1-D), sponsored by Spyre Therapeutics, Inc. Primary endpoint: Long-term safety and tolerability. Status: unknown.
02
Drugs
pegzilarginase
03
Conditions
arginase 1 deficiency (ARG1-D)
Beyond the preview
Go deeper on 2018-003163-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003163-67.